trial · primary record
Opdivo
Follicular Lymphoma
| Phase | Phase 1 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 39 |
| Primary completion | 2027-06 |
| Primary endpoint | To evaluate the feasibility and safety of combination nivolumab and rituximab as determined by the proportion of toxicity grade 3 or higher per CTCAE v4.0 occurring on induction treatment (ie first 16 weeks of therapy) |
| Registry ID | NCT03245021 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:34:49.437Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03245021
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.